Sign inJoin waitlistJoin the waitlist

Tashanna Myers

Chief Resident, PGY-4

Credentials: · · ·

History

Obstetrics and Gynecology
UMass Chan - Baystate
PGY-42023–Present
2023–Present
Gynecologic Oncology
2027–2030
Temple University School of Medicine
1998–2002

Research

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
New England Journal of Medicine · 2023 · 405 citations
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)
Journal of Clinical Oncology · 2021 · 336 citations
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study
Journal of Clinical Oncology · 2019 · 175 citations

Kathleen Moore
11 papers · 4 as a resident
Joan Walker
8 papers
Lisa Landrum
7 papers · 5 as a fellow
CA
Carol Aghajanian
5 papers
Michael Gold
5 papers
Bhavana Pothuri
4 papers
CA
Charles Anderson
4 papers
DM
Donald Mcmeekin
4 papers
Robert Mannel
4 papers
YL
Yvonne Lin-Liu
4 papers
Bradley Monk
3 papers
David O'Malley
3 papers

Clinical trials

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Site PI · Recruiting · Phase 3
NRG Oncology
2025–2034
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2023–2030
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2022–2027
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III
Site PI · Recruiting · Phase 2
University Medical Center Groningen
2021–2029